Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

 
 
 
 
 
 
 
 
 
 

VALSAVA-H

Quick Overview

Our aim is to reach out to the globe within shortest possible time frame. 


To promote this objective, not only we distribute and market our cardiovascular  range of products globally through our distribution channels but we also undertake ‘contract manufacturing’& ‘formulation development ’of our wide range of generic products such as 


VALSAVA- H 80 Each film coated tablet contains: Valsartan USP 80 mg. Hydrochlorothiazide USP 12.5 mg.


VALSAVA H 160 Each film coated tablet contains: Valsartan USP 160 mg. Hydrochlorothiazide USP 12.5 mg.


This Valsava H contains same active ingredient as Diovan HCT from Novartis 

VALSAVA-H 80

Double click on above image to view full picture

Zoom Out
Zoom In

Details

 Each film coated tablet contains:

Valsartan USP                          80 mg.

Hydrochlorothiazide USP      12.5 mg.

VALSAVA H 160

Each film coated tablet contains:

Valsartan USP                        160 mg.

Hydrochlorothiazide USP      12.5 mg.

Description:

Valsartan:  An orally active and specific angiotensin II (Ang II) receptor antagonist. It acts selectively on the AT1 receptor subtype, which is responsible for the known actions of angiotensin II.

Hydrochlorothiazide: The site of action of thiazide diuretics is primarily in the renal distal convoluted tubule. It has been shown that there is a high-affinity receptor in the renal cortex as the primary binding site for the thiazide diuretic action and inhibition of NaCl transport in the distal convoluted tubule.

Indications:

  • Valsava-H  is indicated for the treatment of essential hypertension in adults.
  • Valsava - H may be used in patients whose blood pressure is not adequately controlled on monotherapy.
  • Valsava - H may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals.

Dosage and administration:

Initial Therapy

  • The usual starting dose is Valsava - H 160/12.5 mg once daily. The dosage can be increased after 1 to 2 weeks of therapy to a maximum of one 320/25 mg tablet once daily as needed to control blood pressure. Valsava - H is not recommended as initial therapy in patients with intravascular volume depletion.

Contraindications:

  • Valsartan and hydrochlorothiazide is contraindicated in patients who are hypersensitive to any component of this product.
  • Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.
  • Contraindicated in second and third trimester of pregnancy.
  • Contraindicated in severe hepatic impairment, biliary cirrhosis and cholestasis, severe renal impairment (creatinine clearance <30 ml/min), anuria and in refractory hypokalaemia, hyponatraemia, hypercalcaemia, and symptomatic hyperuricaemia.

Presentation:

Alu-Alu Blister of 10 Tablets

 

 
OUR PRESENCE:
FIND US ON: